SWAN announces investment in Skope

SWAN is pleased to announce an investment in Skope, a medical device company that manufactures a proprietary stethoscope disinfection technology to help simply and effectively reduce the chance of infections.

The Skope Station is a wall-mounted point-of-care device equipped with a disposable cartridge filled with an EPA-approved disinfectant. It swiftly eliminates infectious organisms, including Covid-19, bacterial spores, and MRSA, from a stethoscope’s diaphragm in one swipe, minimizing workflow disruption.

SWAN announces investment in Aiki

SWAN is pleased to announce an investment in Aiki, an app that harnesses technology for two-way communication in school safety situations.

Aiki’s app safeguards school campuses from active shooters, providing rapid alerts, training, and coaching for students. In less than 4 seconds, the system’s advanced algorithms deliver critical lockdown instructions and real-time crisis maps, allowing first responders to pinpoint areas requiring immediate attention through heat maps. The app also allows two-way communication between building occupants and first responders, enhancing response accuracy and efficiency.

SWAN announces follow-on investment in Eisana

SWAN Impact Network is pleased to announce a follow-on investment in Eisana.

Eisana is an oncology solution company providing a platform for multiple products to address cancer treatment issues, including a patent-pending, cryo-compression device for hands and feet to wear before, during, and after infusion to prevent chemotherapy-induced peripheral neuropathy.

They are also developing a patent pending, state-of-the-art scalp cooling device to wear before, during, and after infusion to prevent chemotherapy-induced hair loss. The device is portable and can cool for long periods of time, necessary to have success even for drugs that take longer to leave the body.

SWAN previously invested in the company earlier in 2023.

​SWAN announces follow-on investment in Hubly Surgical

SWAN is pleased to announce follow-on funding in Hubly Surgical, which recently raised $3 million in an oversubscribed Funding Round.

In May 2023, Hubly Surgical announced that HUBLY DRILL, the first and only single-use cranial drill with advanced features for safety and efficiency in any setting, is FDA-cleared and now available for sale. Read more HERE.

Following FDA Clearance, this investment comes primarily from the Hubly commission-only distributor sales force, pre-existing investors, and the neurosurgeons and physicians who share the company’s vision.

SWAN previously invested in Hubly in 2021.